Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

LoneStar Heart Raises $20 Million in Round Led by Hong Kong PE Firm

publication date: Oct 9, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
LoneStar Heart of California has raised up to $20 million in a milestone-based equity financing, which the company will use to support clinical development its lead product, Algisyl-LVR. The product, considered a medical device, is a biopolymer that is implanted into the left ventricle wall of the heart to treat advanced heart failure. The financing was led by Themes Investment Partners, a Hong Kong PE fund focused on China markets. The capital will be used to conduct clinical trials in Europe (already underway), followed by China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners